Bal Pharma Financial Results
- Market cap
- ₹156 crore
- P/E
- 21.6
- P/B
- 1.90
- ROE
- 7.9%
- Dividend yield
- 1.23%
For the year ended Mar 2018, Bal Pharma reported revenue of ₹212 crore and net profit of ₹0 crore, against ₹171 crore and -₹13 crore a year earlier.
Bal Pharma annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 212 | 171 | 251 | — | 302 | 339 | 294 | 303 | 334 |
| Expenses | 194 | 166 | 226 | — | 275 | 307 | 264 | 269 | 301 |
| Operating profit | 17 | 5 | 24 | — | 27 | 32 | 30 | 34 | 34 |
| Operating margin % | 8% | 3% | 10% | — | 9% | 9% | 10% | 11% | 10% |
| Other income | 2 | 2 | 1 | — | -2 | 2 | 0 | -2 | 2 |
| Interest | 9 | 12 | 12 | — | 10 | 14 | 15 | 15 | 17 |
| Depreciation | 7 | 8 | 10 | — | 9 | 10 | 10 | 11 | 11 |
| Profit before tax | 3 | -14 | 4 | — | 5 | 9 | 5 | 6 | 7 |
| Tax % | 87% | 5% | -15% | — | 45% | 18% | -41% | -7% | -6% |
| Net profit | 0 | -13 | 5 | — | 3 | 7 | 7 | 6 | 7 |
| EPS (₹) | 0.00 | 0.00 | 3.02 | — | 1.64 | 4.68 | 4.53 | 3.95 | 4.53 |
| Dividend payout % | — | — | — | — | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Bal Pharma financial results — frequently asked questions
What is Bal Pharma's annual revenue and net profit?
For the financial year ended Mar 2018, Bal Pharma's revenue was ₹212 crore and net profit ₹0 crore; net profit rose 100.00% from -₹13 crore in Mar 2020.
What is the EPS of Bal Pharma?
Annual EPS for Mar 2018 was ₹0.00.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Bal Pharma With ATS
Track BALPHARMA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.